# Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

> **NCT00401973** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 199 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorders

## Interventions

- **DRUG:** olanzapine
- **DRUG:** amantadine
- **DRUG:** metformin
- **DRUG:** zonisamide
- **BEHAVIORAL:** Wellness education

## Key facts

- **NCT ID:** NCT00401973
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2009-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401973, "Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00401973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*